BIVDA Report Outlines UK Access Barriers to Genetic, Genomic Diagnostics
Challenges identified in the white paper include a lack of centralized guidance to apply for funding for genomic technologies and a shortage of infrastructure to educate physicians and patients.
US Federal Trade Commission Orders Illumina to Unwind Grail Acquisition
Illumina plans to appeal the decision, seeking a resolution by late 2023 or early 2024, but now faces a third source of pressure to divest Grail.
European Commission Outlines Intended Restorative Measures for Blocked Illumina-Grail Deal
In a Statement of Objections, the agency laid out the intended divestment and transitional measures for Illumina to unwind and dissolve the Grail acquisition.
ESMO Data Sharpens View of How Grail, Exact Sciences Multi-Cancer Early Detection Tests Perform
Grail released updated data on Galleri from the PATHFINDER study, while Exact reported retrospective analysis on the performance of its test.
EU to Disallow Illumina's Grail Purchase
Separately, the US Federal Trade Commission said it will appeal an administrative law judge's initial decision in an antitrust case that was favorable to Illumina.